Genelux Corp. (GNLX) News
Filter GNLX News Items
GNLX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GNLX News Highlights
- For GNLX, its 30 day story count is now at 2.
- Over the past 18 days, the trend for GNLX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DRUG, MET and NOV are the most mentioned tickers in articles about GNLX.
Latest GNLX News From Around the Web
Below are the latest news stories about GENELUX CORP that investors may wish to consider to help them evaluate GNLX as an investment opportunity.
Insider Sell Alert: Director James Tyree Offloads 9,000 Shares of Genelux Corp (GNLX)In the realm of stock market movements, insider trading activity is often a significant indicator for investors. |
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer- Pivotal Phase 3 Study of Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer Initiated in September 2022 - - Phase 2 Trial of Olvi-Vec- Demonstrated Clinical Reversal of Platinum Resistance and Refractoriness and Met Primary Endpoint of Objective Response Rate with Durable Responses - WESTLAKE VILLAGE, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the United States Food and Drug Administrat |
Genelux Corporation (NASDAQ:GNLX) most popular amongst retail investors who own 57%, insiders hold 25%Key Insights Significant control over Genelux by retail investors implies that the general public has more power to... |
Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates- Expanded executive team as Lourie Zak appointed Chief Financial Officer - - Extended clinical focus on systemic administration in small cell lung cancer - - $29.9 million in cash and equivalents - WESTLAKE VILLAGE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter of 2023 and provided general business updates. “The third quarter was highlighted by continued expansi |
12 Best Performing Biotech Stocks in 2023In this piece, we will take a look at the 12 best performing biotechnology stocks in 2023. If you want to skip our introduction to the biotechnology industry and some top players, then check out 5 Best Performing Biotech Stocks in 2023. Biotechnology is one of the hottest industries these days and one that has […] |
Director John Thomas Sells 6667 Shares of Genelux Corp (GNLX)On September 18, 2023, John Thomas, a director at Genelux Corp (NASDAQ:GNLX), sold 6,667 shares of the company. |
Director John Smither Sells 900 Shares of Genelux Corp (GNLX)On September 13, 2023, John Smither, a director at Genelux Corp (NASDAQ:GNLX), sold 900 shares of the company's stock. |
10% Owner Aladar Szalay Sells 52,616 Shares of Genelux Corp (GNLX)On September 12, 2023, 10% owner Aladar Szalay sold 52,616 shares of Genelux Corp (NASDAQ:GNLX). |
Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WESTLAKE VILLAGE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023, the Company’s Board of Directors (the “Board”) granted inducement awards consisting of non-qualified stock options to purchase 444,300 shares of common stock to seven new employees under the Company’s 2023 Inducement Plan, including an option to purchase 150,000 shares of common stock to Lourie Zak, the Company |
Genelux Corporation to Present at the H.C. Wainwright Global Investment ConferenceWESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, Chairman and CEO, will present a corporate overview with institutional investors during the H.C. Wainwright 25th Annual Global Investment Conference held the week of September 11th, 2023. The Company will also attend virtual one-on-one meetings during the conference. Institutional investors interested in a |